StockIQpro
NASDAQ:ORMP

Oramed Pharmaceuticals Inc.

Track all markets on TradingView
Track all markets on TradingView

Oramed Pharmaceuticals Inc.'s revenue was $2.0M in fiscal 2025. Free cash flow was −$9.2M, −457.7% of revenue, and the diluted share count rose 3.8%.Summary generated from Oramed Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$2.0M
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross margin0.7%
Operating margin−754.4%
Net margin3202.5%
ROICn/a
Return on equity37.0%
Debt / equityn/a
Free cash flow−$9.2M
FCF margin−457.7%
Share count change+3.8%

Financials

Fiscal years, $M
Item2022202320242025
Revenue31n/a2
Operating income−41−16−13−15
Net income−375−1964
Free cash flow−28−11−8−9

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations